Status | Study |
RECRUITING |
Study Name: Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Condition: Primary Central Nervous System Lymphoma Date: 2022-12-08 Interventions: Participants will receive 900 mg/m^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the indu |
Not yet recruiting |
Study Name: PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2017-04-10 Interventions: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Not yet recruiting |
Study Name: Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2016-11-29 Interventions: Dietary Supplement: ketogenic diet |
Recruiting |
Study Name: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Condition: Primary CNS Lymphoma Date: 2016-10-13 Interventions: Drug: methotrexate Drug: temozolomide |
Recruiting |
Study Name: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Condition: Primary Central Nervous System Lymphoma Date: 2016-07-14 Interventions: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Recruiting |
Study Name: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Condition: Primary Central Nervous System Lymphoma Date: 2016-05-17 Interventions: Drug: pembrolizumab Pembrolizumab 200 mg every 3 weeks |
Recruiting |
Study Name: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2016-01-07 Interventions: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Recruiting |
Study Name: Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute Condition: Primary Central Nervous System Lymphoma Date: 2015-12-09 Interventions: Radiation: Standard treatment protocol with combined chemoradiation |
Recruiting |
Study Name: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2015-03-01 Interventions: Drug: R-MT followed by auto-HSCT Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3 |
Recruiting |
Study Name: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Condition: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) Date: 2014-12-09 Interventions: Drug: Ibrutinib Arm A: Ibrutin |